Table 1. The cardiac phenotypes of embryos injected with Nkx2.5-MO, Nkx2.7- MO and Nkx2.5/2.7-MO.
| Morpholino (ng) | Survival numbers of Embryos | Abnormal Phenotypes | |||
| Nkx2.5 | Nkx2.7 | Looping Defects | Shrinking Ventricle | pericardial edema | |
| 4 | 4 | 142/167 (85.0%) | 85(59.8%) | 75(52.8%) | — |
| 6 | 6 | 207/255 (81.2%) | 166 (80.2%) | 151(72.9%) | — |
| 8 | 8 | 183/233 (78.6%) | 177 (97.8%) | 162 (88.5%) | — |
| 0 | 10 | 115/137 (83.9%) | 56(48.7%) | 12(10.4%) | — |
| 0 | 12 | 139/177 (78.5%) | 87(62.5%) | 27(19.4%) | — |
| 0 | 14 | 183/246 (74.3%) | 143(78.1%) | 75(40.9%) | — |
| 10 | 0 | 24/188 (87.2%) | 0 | 0 | 21/164(12.8%) |
| 12 | 0 | 74/84(88.1%) | 0 | 0 | 15/76 (19.7%) |
| 14 | 0 | 82/98(83.7%) | 0 | 0 | 19/82(23.2%) |
Embryos derived from the transgenic line of Tg(cmlc2::GFP) were used, and the cardiac morphology was observed by fluorescence microscope. The major cardiac phenotype of Nkx2.5/2.7-MO morphants revealed unlooping defects and shrunken ventricle; the major phenotype for Nkx2.7-MO morphants was looping defects with a lesser rate of shrunken ventricle. The Nkx2.5-MO morphants displayed no obvious cardiac phenotype except pericardial edema. (“—“ represents no observation.) The percentage of each abnormal phenotype was counted individually.